Drugs / AMCASERTIB
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02483247 | Sep 2015 → May 2019 | cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02432326 | Apr 2015 → Dec 2019 | cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02354898 | Mar 2015 → Oct 2018 | hepatocellular carcinoma | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01781455 | Feb 2012 → Jun 2020 | cancer of unknown primary site | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02279719 | Dec 2014 → Jul 2019 | hepatocellular carcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02232620 | Mar → Jul 2017 | gastrointestinal stromal tumor | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02232646 | Jan 2017 → Aug 2018 | renal cell carcinoma, urothelial carcinoma | Sumitomo Pharma America, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02432690 | Jun 2015 → Jan 2017 | ovarian cancer | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02232633 | Feb 2015 → Dec 2017 | cholangiocarcinoma, hepatocellular carcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-06-06 | Sumitomo Pharma America, Inc. | Results Dainippon Sumitomo Pharma announces clinical data of anti-cancer drugs BBI608 and BBI503 were presented at the 2014 ASCO Annual Meeting sumitomo-pharma.com ↗
Dainippon Sumitomo Pharma Co., Ltd. (Head office: Osaka, Japan; President: Masayo Tada) ("DSP") announced that clinical study data of BBI608 and BBI503 were presented in poster sessions at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting which began in Chicago on May 30, 2014. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-05-19 | Sumitomo Pharma America, Inc. | Sumitomo Dainippon Pharma announces Clinical Data of Investigational anti-cancer drugs Napabucasin and Amcasertib in Multiple Cancer Types at ASCO 2016 sumitomo-pharma.com ↗ |
| 2014-06-06 | Sumitomo Pharma America, Inc. | Dainippon Sumitomo Pharma announces clinical data of anti-cancer drugs BBI608 and BBI503 were presented at the 2014 ASCO Annual Meeting sumitomo-pharma.com ↗ |
| 2014-05-15 | Sumitomo Pharma America, Inc. | Dainippon Sumitomo Pharma announces clinical data of anti-cancer drugs BBI608 and BBI503 will be presented at the 2014 ASCO Annual Meeting sumitomo-pharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMCASERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707349 ↗ |
| Known as | BBI503 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02483247 ↗ |
| Modality | Small molecule | — CHEMBL3707349 ↗ |
| Route | Oral | “BBI503 will be administered orally” NCT02232620 ↗ |